Page last updated: 2024-11-11

glycycoumarin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycycoumarin: from the root of Glycyrrhizae Radix, acts as a potent antispasmodic through inhibition of phosphodiesterase 3; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

glycycoumarin : A member of the class of coumarins that is coumarin substituted by a hydroxy group at position 7, a methoxy group at position 5, a prenyl group at position 6 and a 2,4-dihydroxyphenyl group at position 3. Isolated from Glycyrrhiza uralensis, it exhibits antispasmodic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycyrrhizagenusA genus of leguminous herbs or shrubs whose roots yield GLYCYRRHETINIC ACID and its derivative, CARBENOXOLONE.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]
Glycyrrhiza uralensisspeciesA plant species of the family FABACEAE.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]
Glycyrrhiza uralensisspeciesA plant species of the family FABACEAE.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID5317756
CHEMBL ID1223642
CHEBI ID69087
SCHEMBL ID759406
MeSH IDM0504344

Synonyms (28)

Synonym
chebi:69087 ,
CHEMBL1223642 ,
glycycoumarin
94805-82-0
3-(2,4-dihydroxy-phenyl)-7-hydroxy-5-methoxy-6-(3-methyl-but-2-enyl)-1-benzopyran-2-one
3-(2,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-6-(3-methylbut-2-enyl)chromen-2-one
LMPK12160018
bdbm50325943
cwq2b8g346 ,
unii-cwq2b8g346
3-(2,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-6-(3-methylbut-2-en-1-yl)-2h-chromen-2-one
SCHEMBL759406
AKOS026674269
DTXSID20241630 ,
3-(2,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-6-(3-methyl-2-butenyl)-2h-1-benzopyran-2-one, 9ci
Q27137427
2h-1-benzopyran-2-one, 3-(2,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-6-(3-methyl-2-buten-1-yl)-
3-(2,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-6-(3-methyl-2-buten-1-yl)-2h-1-benzopyran-2-one
HY-N4113
CS-0032122
flavone base + 3o, 1meo, 1prenyl
A934778
MS-25897
2h-1-benzopyran-2-one,3-(2,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-6-(3-methyl-2-butenyl)-
XG170485
glycocoumarin - glycyrrhiza uralensis (liquorice)
E80590
dtxcid50164121

Research Excerpts

Overview

Glycycoumarin (GCM) is a major bioactive coumarin compound isolated from licorice. The anti-cancer activity of GCM has not been scientifically addressed.

ExcerptReferenceRelevance
"Glycycoumarin (GCM) is a representative coumarin compound in licorice with favorable bioavailability feature."( Protective effects of glycycoumarin on liver diseases.
Fan, L; Hu, H; Yan, M; Yin, S; Zhang, E; Zhao, C; Zhao, S, 2020
)
1.59
"Glycycoumarin (GCM) is a major coumarin compound isolated from licorice with favorable bioavailability property."( Involvement of activation of PLIN5-Sirt1 axis in protective effect of glycycoumarin on hepatic lipotoxicity.
Fan, L; Hu, H; Yin, S; Zhang, E; Zhao, C, 2020
)
1.51
"Glycycoumarin (GCM) is a representative of bioactive coumarin compounds isolated from licorice, an edible and medicinal plant widely used for treating various diseases including liver diseases. "( Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis.
Fan, L; Hu, H; Lu, X; Ye, L; Yin, S; Zhang, E, 2018
)
3.37
"Glycycoumarin is a major bioactive coumarin of licorice (Glycyrrhiza uralensis), one of the most popular herbal medicines worldwide. "( Metabolites identification of glycycoumarin, a major bioactive coumarin from licorice in rats.
Feng, LM; Guo, DA; Ji, S; Liu, CF; Qian, Y; Qiao, X; Wang, Q; Ye, M, 2014
)
2.13
"Glycycoumarin (GCM) is a major bioactive coumarin compound isolated from licorice and the anti-cancer activity of GCM has not been scientifically addressed. "( Glycycoumarin exerts anti-liver cancer activity by directly targeting T-LAK cell-originated protein kinase.
Fan, L; Hu, H; Song, X; Ye, M; Yin, S; Zhang, E; Zhang, Y, 2016
)
3.32
"Glycycoumarin (GCM) is a representative of courmarin compounds isolated from licorice."( Glycycoumarin inhibits hepatocyte lipoapoptosis through activation of autophagy and inhibition of ER stress/GSK-3-mediated mitochondrial pathway.
Fan, L; Hu, H; Song, X; Yin, S; Zhang, E, 2016
)
2.6

Treatment

ExcerptReferenceRelevance
"Pretreatment with glycycoumarin also enhanced the relaxation effect of rolipram, a specific inhibitor of PDE isozyme 4, as pretreatment with milrinone, a specific inhibitor of isozyme 3, did."( Glycycoumarin from Glycyrrhizae Radix acts as a potent antispasmodic through inhibition of phosphodiesterase 3.
Akao, T; Asano, T; He, JX; Kuraishi, Y; Morota, T; Nojima, H; Sato, Y; Tani, T, 2006
)
2.1

Bioavailability

Glycycoumarin (GCM) is a major coumarin compound isolated from licorice with favorable bioavailability property.

ExcerptReferenceRelevance
" Glycycoumarin (GCM) is a representative coumarin compound in licorice with favorable bioavailability feature."( Protective effects of glycycoumarin on liver diseases.
Fan, L; Hu, H; Yan, M; Yin, S; Zhang, E; Zhao, C; Zhao, S, 2020
)
1.78
" Glycycoumarin (GCM) is a major coumarin compound isolated from licorice with favorable bioavailability property."( Involvement of activation of PLIN5-Sirt1 axis in protective effect of glycycoumarin on hepatic lipotoxicity.
Fan, L; Hu, H; Yin, S; Zhang, E; Zhao, C, 2020
)
1.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antispasmodic drugA drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
coumarins
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
resorcinolsAny benzenediol in which the two hydroxy groups are meta to one another.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)183.90000.00053.49849.7600AID504121
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1651899Cytotoxicity against human insulin resistant HepG2 cells assessed as cell viability at 10 uM by CCK8 assay relative to control
AID1372435Antitussive activity in ammonia liquor-induced cough ICR mouse model assessed as reduction in cough frequency at 50 mg/kg, po treated with ammonia 1 hr before and 5 hrs after test compound dosing measured for 3 mins relative to control2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Antitussive and expectorant activities of licorice and its major compounds.
AID1432497Inhibition of Bacillus subtilis N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) at 100 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1432491Inhibition of Bacillus subtilis N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 20 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID504121Inhibition of human recombinant PTP1B assessed as p-nitorphenol production after 30 mins2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Prenylflavonoids from Glycyrrhiza uralensis and their protein tyrosine phosphatase-1B inhibitory activities.
AID1651898Inhibition of alpha-Glucosidase (unknown origin) at 10 uM using pNPG as substrate incubated for 30 mins relative to control
AID634229Antibacterial activity against Prevotella intermedia ATCC 25611 assessed as growth inhibition at 1.25 to 10 ug/ml after 24 hrs by microplate dilution assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Isoflavonoids and coumarins from Glycyrrhiza uralensis: antibacterial activity against oral pathogens and conversion of isoflavans into isoflavan-quinones during purification.
AID1432492Inhibition of Bacillus subtilis N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 100 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1372434Antitussive activity in ammonia liquor-induced cough ICR mouse model assessed as reduction in cough frequency at 50 mg/kg, po treated with ammonia 1 hr before and 2.5 hrs after test compound dosing measured for 3 mins relative to control2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Antitussive and expectorant activities of licorice and its major compounds.
AID1372444Antitussive activity in ammonia liquor-induced cough ICR mouse model assessed as reduction in cough frequency at 20 mg/kg, po treated with ammonia 1 hr before and 5 hrs after test compound dosing measured for 3 mins2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Antitussive and expectorant activities of licorice and its major compounds.
AID1301449Activation of NRF2 transcription in human HepG2C8 cells at 10 uM after 6 hrs by luciferase reporter gene assay relative to control2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Constituents of Glycyrrhiza uralensis (Licorice): Discovery of the Effective Components of a Traditional Herbal Medicine.
AID1432496Inhibition of Escherichia coli N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 200 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1372433Antitussive activity in ammonia liquor-induced cough ICR mouse model assessed as reduction in cough frequency at 50 mg/kg, po treated with ammonia 1 hr before and 1 hr after test compound dosing measured for 3 mins relative to control2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Antitussive and expectorant activities of licorice and its major compounds.
AID1372442Antitussive activity in ammonia liquor-induced cough ICR mouse model assessed as reduction in cough frequency at 20 mg/kg, po treated with ammonia 1 hr before and 1 hr after test compound dosing measured for 3 mins2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Antitussive and expectorant activities of licorice and its major compounds.
AID1432493Inhibition of Bacillus subtilis N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 200 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1432494Inhibition of Escherichia coli N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 20 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1651897Inhibition of recombinant human PTP1B (1 to 321 residues) expressed in Escherichia coli at 10 uM using p-nitrophenyl phosphate as substrate incubated for 30 mins relative to control
AID1432495Inhibition of Escherichia coli N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 100 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1372443Antitussive activity in ammonia liquor-induced cough ICR mouse model assessed as reduction in cough frequency at 20 mg/kg, po treated with ammonia 1 hr before and 2.5 hrs after test compound dosing measured for 3 mins2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Antitussive and expectorant activities of licorice and its major compounds.
AID634224Antibacterial activity against Streptococcus sobrinus ATCC 33478 assessed as growth inhibition at 1.25 to 10 ug/ml after 24 hrs by microplate dilution assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Isoflavonoids and coumarins from Glycyrrhiza uralensis: antibacterial activity against oral pathogens and conversion of isoflavans into isoflavan-quinones during purification.
AID1651896Inhibition of alpha-Glucosidase (unknown origin) using pNPG as substrate incubated for 30 mins
AID634223Antibacterial activity against Streptococcus mutans ATCC 25175 assessed as growth inhibition at 1.25 to 10 ug/ml after 24 hrs by microplate dilution assay2011Journal of natural products, Dec-27, Volume: 74, Issue:12
Isoflavonoids and coumarins from Glycyrrhiza uralensis: antibacterial activity against oral pathogens and conversion of isoflavans into isoflavan-quinones during purification.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (15.79)29.6817
2010's13 (68.42)24.3611
2020's3 (15.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.59 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]